| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $22,161,096 ) (Continued on the next page) |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD017675 | Reducing Urban Cervical Cancer Disparities Using a Tailored mHealth Intervention to Enhance Colposcopy Attendance | 001 | 2 | NIH | 12/7/2023 | $633,245 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA245871 | MTAP, 5'-deoxy-5'-methylthioadenosine, and the dysregulation of symmetric dimethylarginine in cancer | 000 | 5 | NIH | 5/13/2024 | $406,375 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA251674 | Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma | 000 | 4 | NIH | 5/29/2024 | $406,375 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA214799 | Compensatory Mechanisms that Promote Homologous Recombination in BRCA1 Mutant Cancers | 000 | 6 | NIH | 8/8/2024 | $470,000 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | K99GM148819 | Elucidating the epigenetic regulation of extracellular matrix and virus-induced fibroblast activation | 001 | 2 | NIH | 1/24/2024 | $125,000 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R37CA283552 | Targeting DHX9 to trigger viral mimicry and immunotherapy responsiveness in Small Cell Lung Cancer (SCLC) | 000 | 1 | NIH | 7/31/2024 | $649,679 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | U01CA260369 | Optimization of urinary DNA deep sequencing tests to enhance clinical staging of bladder cancer patients | 000 | 4 | NIH | 7/31/2024 | $337,277 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM155098 | Interplay between DNA base excision repair and transcriptional regulation | 000 | 1 | NIH | 9/13/2024 | $470,000 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA282766 | Interrogating MRCK Protein Kinases in Ovarian Cancer | 001 | 1 | NIH | 8/29/2024 | $235,000 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA282766 | Interrogating MRCK Protein Kinases in Ovarian Cancer | 000 | 1 | NIH | 2/7/2024 | $451,910 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | UH3CA271230 | Validation of blood-based predictive biomarkers of therapeutic response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer | 000 | 3 | NIH | 7/24/2024 | $400,915 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD018511 | Neighborhood, social connectedness, and allostatic load in US Chinese immigrants | 001 | 2 | NIH | 5/25/2024 | $46,877 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD018511 | Neighborhood, social connectedness, and allostatic load in US Chinese immigrants | 000 | 2 | NIH | 12/9/2023 | $602,694 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R00DK128602 | Defining the molecular basis controlling hematopoietic stem cell symmetric and asymmetric divisions | 000 | 3 | NIH | 8/9/2024 | $249,000 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R03CA286669 | Divergent Functions of ERK2 Substrate Binding Domains in Pathogenesis of KRAS-Driven Pancreatic Cancer | 000 | 1 | NIH | 12/13/2023 | $94,000 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA281212 | Elucidating the critical role of Wee1 in GIST | 001 | 2 | NIH | 4/17/2024 | $21,503 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA281212 | Elucidating the critical role of Wee1 in GIST | 000 | 2 | NIH | 1/26/2024 | $387,045 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA285674 | Promoting Effective Clinical Communication about Sexual Health after Gynecologic Cancer: A Randomized Controlled Trial of a Patient-Focused Intervention | 000 | 1 | NIH | 7/1/2024 | $475,317 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R37AI110985 | Regulation of hematopoiesis by ribosomal protein paralogs | 001 | 10 | NIH | 5/23/2024 | $56,100 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R37AI110985 | Regulation of hematopoiesis by ribosomal protein paralogs | 000 | 10 | NIH | 1/23/2024 | $504,900 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM119560 | Molecular Mechanisms Underlying Adaptor-Mediated Integrin Signaling in a Species-Specific Manner | 001 | 8 | NIH | 6/26/2024 | $48,152 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM119560 | Molecular Mechanisms Underlying Adaptor-Mediated Integrin Signaling in a Species-Specific Manner | 000 | 8 | NIH | 11/20/2023 | $433,373 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21CA282851 | Estrogen Suppression as a Strategy to Enhance Immunotherapy Efficacy in EGFR-Mutated Non-Small Cell Lung Cancer | 000 | 1 | NIH | 5/23/2024 | $483,395 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R25CA288297 | Addressing the Training Gap in Oncology on Sexual Health: Development of the Sexual Health Integrative Fellowship Training (SHIFT) Course for Hematology-Oncology Fellows | 000 | 1 | NIH | 4/2/2024 | $162,000 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21CA286231 | A novel engineered IL-21-based immunocytokine as a therapeutic approach for tumor targeting in renal cancer | 000 | 1 | NIH | 6/4/2024 | $483,395 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | T32CA278766 | Training Grant in Precision Cancer Control | 000 | 2 | NIH | 7/31/2024 | $337,966 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21CA289161 | NPC1 as a novel therapeutic target in ccRCC | 000 | 1 | NIH | 2/16/2024 | $219,725 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA289703 | Hepatic Tissue Integrity and Clonal Fitness: Key Factors in Controlling β-Catenin Induced Oncogenesis | 000 | 1 | NIH | 2/22/2024 | $601,884 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R00CA267678 | Positive Activities for Asian American Cancer Patients and Caregivers | 001 | 3 | NIH | 8/9/2024 | $26,194 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R00CA267678 | Positive Activities for Asian American Cancer Patients and Caregivers | 000 | 3 | NIH | 4/12/2024 | $249,000 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R00CA263017 | The role of MER/PROS1 in promoting stromal induced emergence from metastatic melanoma dormancy | 000 | 3 | NIH | 4/10/2024 | $249,000 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM150538 | Telomerase RNP Prisonbreaks from Phase-Separated Nuclear Body | 001 | 2 | NIH | 8/6/2024 | $239,252 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM150538 | Telomerase RNP Prisonbreaks from Phase-Separated Nuclear Body | 000 | 2 | NIH | 5/15/2024 | $470,000 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21CA277402 | A Phase I Proof-of-Concept Study of CBL0137 Combined with Ipilimumab and Nivolumab Therapy in Locally Advanced or Metastatic Melanoma | 000 | 2 | NIH | 6/3/2024 | $208,738 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA276273 | Fibroblasts Support the Growth of Brain Metastasis by Rendering Cancer Cells Resistant to Chemotherapy and Inducing Immunosuppression in Tumor Microenvironment | 000 | 2 | NIH | 5/10/2024 | $391,874 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | UG3HL170034 | Asian American Community Cohort and Equity Study (ACCESS) | 001 | 2 | NIH | 7/25/2024 | $344,654 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | UG3HL170034 | Asian American Community Cohort and Equity Study (ACCESS) | 001 | 2 | NIH | 7/25/2024 | $71,111 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | UG3HL170034 | Asian American Community Cohort and Equity Study (ACCESS) | 001 | 2 | NIH | 7/25/2024 | $71,111 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | UG3HL170034 | Asian American Community Cohort and Equity Study (ACCESS) | 001 | 2 | NIH | 7/25/2024 | $71,111 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | UG3HL170034 | Asian American Community Cohort and Equity Study (ACCESS) | 001 | 2 | NIH | 7/25/2024 | $71,111 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA283396 | Divergent Functions of ERK Substrate Binding Domains in Pathogenesis of Myeloproliferative Neoplasms | 000 | 2 | NIH | 6/20/2024 | $671,691 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21CA280446 | Interaction of cannabidiol (CBD) with targeted inhibitors of essential cancer signaling pathways | 001 | 2 | NIH | 4/25/2024 | -$10,517 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21CA280446 | Interaction of cannabidiol (CBD) with targeted inhibitors of essential cancer signaling pathways | 000 | 2 | NIH | 3/19/2024 | $210,338 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R03CA280410 | Role of the Parkinson's susceptibility gene LRRK2 in NFAT-mediated malignant mesothelioma tumorigenesis | 000 | 2 | NIH | 5/6/2024 | $94,000 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA269975 | Small-molecule exploitation of ZBP1-driven nuclear necroptosis for cancer immunotherapy | 001 | 2 | NIH | 4/17/2024 | $37,947 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA269975 | Small-molecule exploitation of ZBP1-driven nuclear necroptosis for cancer immunotherapy | 000 | 2 | NIH | 2/14/2024 | $683,088 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD018146 | Examining the Relationship between Residential History at Midlife and Prostate Cancer Outcomes | 001 | 2 | NIH | 6/13/2024 | $36,601 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD018146 | Examining the Relationship between Residential History at Midlife and Prostate Cancer Outcomes | 000 | 2 | NIH | 2/14/2024 | $470,592 |
| | 2024 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | U54CA272686 | Novel small molecule agents to correct pathogenic VHL missense mutations | 001 | 3 | NIH | 8/12/2024 | $1,170,059 |
|
